DDI (2′,3′-dideoxyinosine,
CAS registry number 69655-05-6) and
remdesivir (GS-5734, CAS registry
number 1809249-37-3) were purchased from Biosynth Carbosynth (Carbosynth
Ltd., Berkshire, U.K.) (for DDI, product code ND02929, purity ≥98%;
for
remdesivir, product code AG170167, purity ≥98%), whereas
the other reference compound
GS-441524 (CAS registry number 1191237-69-0)
was purchased from MedChemExpress (MCE, MedChemExpress LLC, New Jersey,
U.S.A.) (catalog number HY-103586, purity 99.77%). The ultrapure solvent
dimethyl sulfoxide (DMSO, CAS registry number 67-68-5) was purchased
from a local distributor, El-Gomhouria Company For Drugs (El-Gomhouria
Co. For Trading Drugs, Chemicals & Medical Supplies, Mansoura
Branch, Egypt) (purity ≥99.9% “anhydrous”). The
simple and direct illustrative molecular docking of DDI in SARS-CoV-2
RdRp was performed utilizing a validated web server called COVID-19
Docking Server. This server uses AutoDock Vina 1.2.0 software as the
docking engine; the 3D structure of the SARS-CoV-2 RdRp (nsp12/7/8)
protein cocrystallized in a complex with RNA as well as the triphosphate
form of
remdesivir (RTP) was obtained from the Protein Data Bank (PDB)
database with the code of
7BV2, employing the validated
remdesivir docking protocol
as the comparison protocol for the ligand DDI.
45
, & Rabie A.M. (2022). Efficacious Preclinical Repurposing of the Nucleoside Analogue Didanosine against COVID-19 Polymerase and Exonuclease. ACS Omega, 7(25), 21385-21396.